Rezolute

RZ402 Clin2 diabetic macular edema

Rezolute is developing drug therapies to cure patients with metabolic diseases associated with chronic glucose imbalance. Both extreme low (hypoglycaemia) and high (hyperglycaemia) blood glucose levels cause disease. Rezolute is developing antibody-based therapies to treat patients with congenital hyperinsulinism (HI), diabetic macular edema and tumor HI. Their approach is to leverage their metabolic expertise to define disease pathways and create therapies that overcome the shortcomings of current standards of care. Rezolute’s lead program, RZ358, is in late-stage clinical trials for congenital HI.